Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol

BACKGROUND: Globally, there is a scarcity of effective treatments for SARS-CoV-2 infections (causing COVID-19). Repurposing existing medications may offer the best hope for treating patients with COVID-19 to curb the pandemic. IMU-838 is a dihydroorotate dehydrogenase inhibitor, which is an effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Kavi, Berry, Lisa, Vryonis, Evangelos, Ali, Asad, Lara, Beatriz, Noufaily, Angela, Parsons, Nicholas, Bradley, Christopher, Haley, Becky, Tabuso, Maria, Arasaradnam, Ramesh P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676417/
https://www.ncbi.nlm.nih.gov/pubmed/36396307
http://dx.doi.org/10.1136/bmjopen-2021-055205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676417/
https://www.ncbi.nlm.nih.gov/pubmed/36396307
http://dx.doi.org/10.1136/bmjopen-2021-055205

Ejemplares similares